The clinical trial conducted by AstraZeneca evaluates two candidate radioligands, [18F]AZD4694 and [11C]AZD2184, for their efficacy in imaging Aβ amyloid depositions in Alzheimer's Disease (AD) patients. Given the increasing prevalence of AD and the growing demand for effective diagnostic tools, successful outcomes from this study could position AstraZeneca favorably in the neuroimaging market. The trial's completion in 2009 suggests that AstraZeneca may have already progressed to subsequent phases or alternative studies, potentially enhancing their portfolio in Alzheimer's diagnostics. The competitive landscape includes other pharmaceutical companies and imaging technology firms focusing on similar radioligands, necessitating continuous monitoring of advancements in this space.